吸入用盐酸氨溴索溶液(力希畅)

Search documents
羚锐制药(600285):核心产品增长稳健,利润端表现优秀
Donghai Securities· 2025-05-13 05:03
Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company's performance in terms of profit is outstanding, with a revenue of 3.501 billion yuan in 2024 (up 5.72% year-on-year) and a net profit attributable to shareholders of 722.55 million yuan (up 27.19% year-on-year) [2] - In Q1 2025, the company achieved a revenue of 1.021 billion yuan (up 12.29% year-on-year, up 37.62% quarter-on-quarter) and a net profit of 217 million yuan (up 13.89% year-on-year, up 45.83% quarter-on-quarter) [2] - The company is a leading player in the traditional Chinese medicine patch market, with a strong performance in core products and a promising growth outlook due to recent acquisitions [6][7] Summary by Sections Financial Performance - In 2024, the company reported a gross margin of 75.82% and a net margin of 20.64%, with improvements in gross margins across various product lines [6] - The company plans to enhance its product pipeline through the acquisition of Yingu Pharmaceutical for 704 million yuan, which is expected to provide significant synergies and fill gaps in its product offerings [6][7] Revenue Breakdown - The revenue from patches reached 2.115 billion yuan in 2024 (up 3.35% year-on-year), while tablets saw a significant increase of 35.60% year-on-year, reaching 355 million yuan [6] - The core product Tongluo Qutong Gao is expected to generate over 1.2 billion yuan in revenue, with double-digit growth anticipated for the "Two Tigers" series [6] Earnings Forecast - The company is expected to achieve net profits of 826.30 million yuan, 951.24 million yuan, and 1.07982 billion yuan for the years 2025, 2026, and 2027 respectively, with corresponding EPS of 1.46, 1.68, and 1.90 yuan [7]
私募通数据周报:本周募资、投资、上市和并购共148起事件
投资界· 2025-03-09 07:47
涉及总金额4 0 8 . 5 3亿元人民币。 作者 | 私募通 来源 | 决策投资圈 (ID:PEDATAMAX) 清科创业(0 1 9 4 5 .HK)旗下私募通统计:截至本周五下午,募资、投资、上市和并购共 1 4 8起事件,涉及总金额4 0 8.53亿人民币。从交易金额来看,本周金额较大事件是: 2 0 25年3月4日,全国社会保障基金理事会投资国投电力控股股份有限公司7 0 . 0 0亿人民 币。从交易事件地域分布看,目前主要分布在上海市、北京市和江苏省,占比为上海市 2 0 .5%,北京市1 6 . 7%,江苏省14.1%。 01 本周募资情况 本周新登记股权投资基金管理人共计0家,取消备案登记4家,全年截至目前累计股权投 资基金管理人数量为11家。本周新增备案基金数量为70只,规模总计1 4 6 . 5 1亿元,本周 备案基金募资最多的为合肥市包河区产发创业投资合伙企业(有限合伙)和绵阳涪江新 兴股权投资合伙企业(有限合伙),募集20.00亿人民币。全年截至目前累计股权投资备 案基金数量为7 0 1只,规模总计5705.25亿元。(2025年2月2 8日- 2 0 2 5年3月6日) 投资金额TO ...